Alpha Fetoprotein Testing Market: By Test Type (ELISA Assays, Chemiluminescent Immunoassays, Immunofluorescence Assays, Rapid Tests), By Indication (Pregnancy, Hepatocarcinoma, Testicular Cancer, Ovarian Cancer, and Others), By End User (Academic and Research Organizations, Contract research organizations (CROs), Hospitals and Clinics and Others) And By Geography (North America, Europe, Asia-Pacific, Middle East And Africa, and South America) and Forecast To 2030.

Purchase Option

$ 4400
$ 6600
$ 8900

Alpha Fetoprotein Testing Market size was valued at USD 668.3 million in 2023 and is poised to grow at a CAGR of 7.1% from 2024-2030. Alpha-fetoprotein (AFP) is a protein that is typically produced by the fetal liver, yolk sac, and gastrointestinal tract during pregnancy. It is the fetal form of serum albumin, which is the main protein in adult blood. AFP levels are usually high in the fetus but decrease significantly after birth and are typically very low in healthy adults. The alpha-fetoprotein (AFP) test is a blood test for pregnant people and is prescribed to people with liver diseases, and germline diseases such as hepatocarcinoma, testicular cancer, ovarian cancer, and so on. The Alpha-Fetoprotein (AFP) testing market encompasses the commercial landscape for products and services related to AFP testing. The presence of AFP is usually low in healthy individuals under 20 ng/ml, whereas pregnant women and diseased individuals have a range of 500-1000 ng/ml. If the individual has around 200ng/ml of AFP, then an AFP-L3 test is prescribed, so that diagnosis can be more accurate.

The increasing prevalence of chronic liver conditions, rise in the occurrence of hepatitis, and adoption of prenatal care and screening of abnormalities, accuracy and efficiency of AFP tests, and higher spending on healthcare are the main drivers of this market. Even though the accuracy is high comparing other tests occurrence of false positives and false negatives is still a major restraint. The high expense of cutting-edge diagnostic equipment and the need for skilled personnel are also acting as restraints. Automation of testing systems and the development of POCT of AFP tests both allow for quicker results and improved patient management. Expanding healthcare infrastructure in developing countries and increasing awareness among people for early diagnosis of diseases serve as the main opportunities for companies in this market.

Recent Development In Alpha-fetoprotein Testing Market:

  • In December 2021, Roche declared the introduction of NAVIFY® Oncology Hub, its most recent digital solution to further improve clinical decision backing and workflow optimization for oncologists and oncology care teams.
  • In November 2021, Roche declared the introduction of the cobas® 5800 System, a novel molecular laboratory tool, in countries receiving the CE mark. The Cobas 5800 System assists in attending to challenges that the laboratories are encountering from a boost in patient testing, and the requirement for a more diverse testing menu including AFP tests while offering significant and timely outcomes.

Alpha Fetoprotein Testing Market Summary

Study Period

2024– 2030

Base Year

2023

CAGR

7.1%

Largest Market

North America

Fastest Growing Market

Asia pacific
Alpha Fetoprotein Testing Market Dynamics

According to the American Cancer Society (ACS), more than 2 million people in the United States are projected to be diagnosed with cancer in 2024, and more than 600,000 will die of it, according to estimates published in Cancer Statistics 2024. An estimated 240,000 newborns die worldwide within 28 days of birth every year due to congenital disorders. Congenital disorders cause a further 170,000 deaths of children between the ages of 1 month and 5 years. WHO estimates at least 30% of it is caused by neonatal disorders. These can be prevented by several methods including AFP testing. According to WHO, HEP-B and HEP-C lead to chronic disease in hundreds of millions of people and together are the most common cause of liver cirrhosis, liver cancer, and viral hepatitis-related deaths. An estimated 354 million people worldwide live with hepatitis B or C of which at least half are at risk of liver cancer. The increasing prevalence of diseases leading to liver cancer is the main cause of the market expansion.

Alpha Fetoprotein Testing Market Segmentation

By Test Type
  • ELISA Assays
  • Chemiluminescent Immunoassays
  • Immunofluorescence Assays
  • Rapid Tests
By Indication
  • Pregnancy
  • Hepatocarcinoma
  • Testicular Cancer
  • Ovarian Cancer
  • Others
By End-user
  • Academic / Research Organizations
  • Contract research organizations (CROs)
  • Hospitals and Clinics
  • Others

Frequently Asked Questions

Alpha Fetoprotein Testing Market size was valued at USD 668.3 million in 2023 and is poised to grow at a CAGR of 7.1% from 2024-2030.

Major companies operating within the Alpha Fetoprotein Testing Market are Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, Thermo Fisher Scientific, and Danaher Corporation.

Continuous advancements in genomic technologies such as CRISPR, the increasing prevalence of genetic diseases, the rise of personalized medicine, and the acceptance of genetically modified organisms (GMOs) are the main drivers of the market.

North America, leads in the Alpha Fetoprotein Testing Market due to the high incidence of liver diseases including liver cancer and hepatitis, well-established healthcare facilities, and awareness and emphasis on early detection and prevention of diseases.

Liver Cancer has the largest share in the Alpha Fetoprotein Testing Market by technique.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030).
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies.
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market.
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market.
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenarios.
1. Executive Summary
2. Global Alpha Fetoprotein Testing Market Introduction 
2.1.Global Alpha Fetoprotein Testing Market  - Taxonomy
2.2.Global Alpha Fetoprotein Testing Market  - Definitions
2.2.1.Test Type
2.2.2.Indication
2.2.3.End-user
2.2.4.Region
3. Global Alpha Fetoprotein Testing Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4. Global Alpha Fetoprotein Testing Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5. Global Alpha Fetoprotein Testing Market  By Test Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. ELISA Assays
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Chemiluminescent Immunoassays
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Immunofluorescence Assays
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Rapid Tests
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
6. Global Alpha Fetoprotein Testing Market  By Indication, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. Pregnancy
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Hepatocarcinoma
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Testicular Cancer
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Ovarian Cancer
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
6.5. Others
6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.5.3. Market Opportunity Analysis 
7. Global Alpha Fetoprotein Testing Market  By End-user, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. Academic / Research Organizations
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Contract research organizations (CROs)
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Hospitals and Clinics
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
7.4. Others
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.4.3. Market Opportunity Analysis 
8. Global Alpha Fetoprotein Testing Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9. North America Alpha Fetoprotein Testing Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. Test Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.ELISA Assays
9.1.2.Chemiluminescent Immunoassays
9.1.3.Immunofluorescence Assays
9.1.4.Rapid Tests
9.2.  Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Pregnancy
9.2.2.Hepatocarcinoma
9.2.3.Testicular Cancer
9.2.4.Ovarian Cancer
9.2.5.Others
9.3.  End-user Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Academic / Research Organizations
9.3.2.Contract research organizations (CROs)
9.3.3.Hospitals and Clinics
9.3.4.Others
9.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10. Europe Alpha Fetoprotein Testing Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1. Test Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.ELISA Assays
10.1.2.Chemiluminescent Immunoassays
10.1.3.Immunofluorescence Assays
10.1.4.Rapid Tests
10.2.  Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Pregnancy
10.2.2.Hepatocarcinoma
10.2.3.Testicular Cancer
10.2.4.Ovarian Cancer
10.2.5.Others
10.3.  End-user Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Academic / Research Organizations
10.3.2.Contract research organizations (CROs)
10.3.3.Hospitals and Clinics
10.3.4.Others
10.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
10.4.6.Rest of EU
11. Asia Pacific (APAC) Alpha Fetoprotein Testing Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1. Test Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.ELISA Assays
11.1.2.Chemiluminescent Immunoassays
11.1.3.Immunofluorescence Assays
11.1.4.Rapid Tests
11.2.  Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Pregnancy
11.2.2.Hepatocarcinoma
11.2.3.Testicular Cancer
11.2.4.Ovarian Cancer
11.2.5.Others
11.3.  End-user Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Academic / Research Organizations
11.3.2.Contract research organizations (CROs)
11.3.3.Hospitals and Clinics
11.3.4.Others
11.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12. Middle East and Africa (MEA) Alpha Fetoprotein Testing Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1. Test Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.ELISA Assays
12.1.2.Chemiluminescent Immunoassays
12.1.3.Immunofluorescence Assays
12.1.4.Rapid Tests
12.2.  Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Pregnancy
12.2.2.Hepatocarcinoma
12.2.3.Testicular Cancer
12.2.4.Ovarian Cancer
12.2.5.Others
12.3.  End-user Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Academic / Research Organizations
12.3.2.Contract research organizations (CROs)
12.3.3.Hospitals and Clinics
12.3.4.Others
12.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13. Latin America Alpha Fetoprotein Testing Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
13.1. Test Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.ELISA Assays
13.1.2.Chemiluminescent Immunoassays
13.1.3.Immunofluorescence Assays
13.1.4.Rapid Tests
13.2.  Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Pregnancy
13.2.2.Hepatocarcinoma
13.2.3.Testicular Cancer
13.2.4.Ovarian Cancer
13.2.5.Others
13.3.  End-user Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Academic / Research Organizations
13.3.2.Contract research organizations (CROs)
13.3.3.Hospitals and Clinics
13.3.4.Others
13.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.Abbott Laboratories
14.2.2.Beckman Coulter
14.2.3.Becton, Dickinson and Company (BD)
14.2.4.Biomedical Diagnostics
14.2.5.Bio-Rad Laboratories
14.2.6.Danaher Corporation
14.2.7.Fujirebio Diagnostics
14.2.8.Kreatech Diagnostics
14.2.9.Mackay Life Sciences
14.2.10.Ortho Clinical Diagnostics
14.2.11.Panacea Pharmaceuticals
14.2.12.PerkinElmer, Inc.
14.2.13.Randox Laboratories
14.2.14.Roche Diagnostics
14.2.15.Siemens Healthineers
14.2.16.Sysmex Corporation
14.2.17.Thermo Fisher Scientific
15. Research Methodology 
16. Appendix and Abbreviations 
  • Abbott Laboratories
  • Beckman Coulter
  • Becton, Dickinson and Company (BD)
  • Biomedical Diagnostics
  • Bio-Rad Laboratories
  • Danaher Corporation
  • Fujirebio Diagnostics
  • Kreatech Diagnostics
  • Mackay Life Sciences
  • Ortho Clinical Diagnostics
  • Panacea Pharmaceuticals
  • PerkinElmer, Inc.
  • Randox Laboratories
  • Roche Diagnostics
  • Siemens Healthineers
  • Sysmex Corporation
  • Thermo Fisher Scientific

Adjacent Markets